Literature DB >> 22160788

An analysis of content in comprehensive cancer control plans that address chronic hepatitis B and C virus infections as major risk factors for liver cancer.

Behnoosh Momin1, Lisa Richardson.   

Abstract

Chronic hepatitis B and hepatitis C virus (HBV and HCV) infections are among the leading causes of preventable death worldwide. Chronic viral hepatitis is the cause of most primary liver cancer, which is the third leading cause of cancer deaths globally and the ninth leading cause of cancer deaths in the United States. The extent to which comprehensive cancer control (CCC) programs in states, tribal governments and organizations, territories, and Pacific Island jurisdictions address chronic hepatitis B and/or hepatitis C infections as risk factors for liver cancer or recommend interventions for liver cancer prevention in their CCC plans remains unknown. We searched CCC plans for this information using the search tool at http://www.cdc.gov/cancer/ncccp/ to access the content of plans for this information. A combination of key search terms including "liver cancer", "hepatitis", "chronic alcohol", and "alcohol abuse" were used to identify potential content regarding liver cancer risk factors and prevention. Relevant content was abstracted for further review and classification. Of 66 (Although CDC funds 65 programs, one of the Pacific Island Jurisdiction grantees is the Federated States of Micronesia (FSM). This national program supports four FSM states, each of which submits a cancer plan to CDC for a total of 69 plans. During this time period, 66 plans were available on the website.) CCC plans, 27% (n = 18) addressed liver cancer using the above-mentioned search terms. In the 23 plans that addressed HBV and/or HCV, there were 25 goals, objectives, strategies, and outcomes aimed at reducing the incidence or prevalence of HBV and/or HCV infection. While nearly a third of CCC programs identify at least one goal, objective, strategy, outcome, or prevention program to reduce cancer burden in their CCC plans, few plans discuss specific actions needed to reduce the burden of liver cancer.

Entities:  

Mesh:

Year:  2012        PMID: 22160788      PMCID: PMC5288733          DOI: 10.1007/s10900-011-9507-y

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  5 in total

Review 1.  Collaborating to conquer cancer: a comprehensive approach to cancer control.

Authors:  Leslie S Given; Bruce Black; Garry Lowry; Philip Huang; Jon F Kerner
Journal:  Cancer Causes Control       Date:  2005-10       Impact factor: 2.506

2.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.

Authors:  Joseph F Perz; Gregory L Armstrong; Leigh A Farrington; Yvan J F Hutin; Beth P Bell
Journal:  J Hepatol       Date:  2006-06-23       Impact factor: 25.083

3.  Hepatocellular carcinoma - United States, 2001-2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-07       Impact factor: 17.586

4.  Chronic liver disease mortality in the United States, 1990-1998.

Authors:  Sirenda Vong; Beth P Bell
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

5.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

  5 in total
  13 in total

1.  Worksite Cancer Prevention Activities in the National Comprehensive Cancer Control Program.

Authors:  Zachary Nahmias; Julie S Townsend; Antonio Neri; Sherri L Stewart
Journal:  J Community Health       Date:  2016-08

Review 2.  Promising practices for the prevention of liver cancer: a review of the literature and cancer plan activities in the National Comprehensive Cancer Control Program.

Authors:  Behnoosh Momin; Alexander J Millman; Danielle Beauchesne Nielsen; Michelle Revels; C Brooke Steele
Journal:  Cancer Causes Control       Date:  2018-12-01       Impact factor: 2.506

3.  Human Papillomavirus Vaccine as an Anticancer Vaccine: Collaborative Efforts to Promote Human Papillomavirus Vaccine in the National Comprehensive Cancer Control Program.

Authors:  Julie S Townsend; C Brooke Steele; Nikki Hayes; Achal Bhatt; Angela R Moore
Journal:  J Womens Health (Larchmt)       Date:  2017-03-06       Impact factor: 2.681

4.  Nutrition and Physical Activity Strategies for Cancer Prevention in Current National Comprehensive Cancer Control Program Plans.

Authors:  Mary Puckett; Antonio Neri; J Michael Underwood; Sherri L Stewart
Journal:  J Community Health       Date:  2016-10

5.  An evaluation of cancer survivorship activities across national comprehensive cancer control programs.

Authors:  J Michael Underwood; Naheed Lakhani; Elizabeth Rohan; Angela Moore; Sherri L Stewart
Journal:  J Cancer Surviv       Date:  2015-03-03       Impact factor: 4.442

6.  Promising Interventions to Prevent Liver Cancer in Idaho.

Authors:  Behnoosh Momin; Danielle Nielsen; Spencer Schaff; Jennifer L Mezzo; Charlene Cariou
Journal:  Health Promot Pract       Date:  2021-12-07

7.  The prioritisation of paediatrics and palliative care in cancer control plans in Africa.

Authors:  M S Weaver; A J J Yao; L A Renner; M Harif; C G Lam
Journal:  Br J Cancer       Date:  2015-06-04       Impact factor: 7.640

8.  Chimeric mouse model for the infection of hepatitis B and C viruses.

Authors:  Abeba Tesfaye; Judith Stift; Dragan Maric; Qingwen Cui; Hans-Peter Dienes; Stephen M Feinstone
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

9.  Antifungal and antiovarian cancer properties of α Fe2O3 and α Fe2O3/ZnO nanostructures synthesised by Spirulina platensis.

Authors:  Heba Salah Abbas; Akilandeswari Krishnan; Muddukrishnaiah Kotakonda
Journal:  IET Nanobiotechnol       Date:  2020-12       Impact factor: 1.847

10.  Radon control activities for lung cancer prevention in national comprehensive cancer control program plans, 2005-2011.

Authors:  Antonio Neri; Sherri L Stewart; William Angell
Journal:  Prev Chronic Dis       Date:  2013-08-08       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.